Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 28 entries
View as:

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05999513 Org: User:
Start: 08/21/23 End: 10/31/23 Due: 10/31/24

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06004921 Org: User:
Start: 10/16/23 End: 02/23/24 Due: 02/23/25

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04736173 Org: User:
Start: 02/08/21 End: 05/31/27 Due: 05/31/28

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03719326 Org: User:
Start: 10/15/18 End: 07/02/21 Due: 07/02/22

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05329766 Org: User:
Start: 06/10/22 End: 06/30/27 Due: 06/30/28

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT04660812 Org: User:
Start: 05/10/21 End: 08/31/25 Due: 08/31/26

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05536141 Org: User:
Start: 10/26/22 End: 07/31/27 Due: 07/31/28

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06120075 Org: User:
Start: 01/19/24 End: 11/30/26 Due: 11/30/27

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04104672 Org: User:
Start: 11/06/19 End: 05/31/27 Due: 05/31/28

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04262856 Org: User:
Start: 05/28/20 End: 08/31/25 Due: 08/31/26

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06608927 Org: User:
Start: 12/13/24 End: 11/30/30 Due: 11/30/31

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04087018 Org: User:
Start: 09/24/19 End: 06/17/24 Due: 06/17/25

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04381832 Org: User:
Start: 07/07/20 End: 08/30/24 Due: 08/30/25

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05891171 Org: User:
Start: 10/13/23 End: 03/31/26 Due: 03/31/27

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Phase: N/A Priority: Normal
NCT ID: NCT05568095 Org: User:
Start: 11/21/22 End: 02/28/27 Due: 02/28/28

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05277012 Org: User:
Start: 02/10/22 End: 03/31/22 Due: 03/31/23

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03846310 Org: User:
Start: 04/01/19 End: 11/18/24 Due: 11/18/25

A Study to Investigate the Safety of AB680 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03677973 Org: User:
Start: 10/16/18 End: 08/19/19 Due: 08/19/20

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04575311 Org: User:
Start: 10/20/20 End: 09/22/21 Due: 09/22/22

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03629756 Org: User:
Start: 07/24/18 End: 09/03/21 Due: 09/03/22

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05411146 Org: User:
Start: 05/25/22 End: 07/07/22 Due: 07/07/23

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03720678 Org: User:
Start: 11/18/18 End: 06/25/21 Due: 06/25/22

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05117554 Org: User:
Start: 11/09/21 End: 02/17/23 Due: 02/17/24

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT07011719 Org: User:
Start: 07/31/25 End: 12/31/30 Due: 12/31/31

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Phase: N/A Priority: Normal
NCT ID: NCT06919991 Org: User:
Start: 05/02/25 End: 10/31/25 Due: 10/31/26